City
Epaper

S. Korea to ban remote prescription of weight loss medication

By IANS | Updated: November 29, 2024 16:50 IST

Seoul, Nov 29 South Korea's health ministry on Friday said it will ban remote prescribing of weight loss ...

Open in App

Seoul, Nov 29 South Korea's health ministry on Friday said it will ban remote prescribing of weight loss medications, including Wegovy, released in the country in October, to prevent potential abuse.

According to the Ministry of Health and Welfare, the decision to ban remote prescribing of weight loss medications will take effect Monday, with a two-week grace period, Yonhap news agency reported.

The move comes amid growing concerns over the abuse and illegal sales of such medications, particularly due to the growing popularity of Wegovy, which was developed by Denmark-based Novo Nordisk.

The government also plans to establish guidelines for telemedicine consultations regarding such medications within the first half of 2025, the health ministry added.

South Korea has been temporarily allowing telemedicine consultations amid the ongoing walkout by trainee doctors at general hospitals, which began in February.

Wegovy was launched in South Korea on November 15. It is a weight management medication that can treat obesity and has gained international attention as a “miracle weight loss drug”.

The Health Ministry stressed that medical institutions should “avoid promoting the drug in ways that might lead patients to believe it can be easily prescribed for general weight loss purposes” and “take special precautions to prevent misuse when prescribing through telemedicine.”

As per the current regulations, Wegovy must only be prescribed to patients with a body mass index (BMI) of 30 or higher. Adults with a BMI between 27 and 30 who have conditions such as hypertension or dyslipidemia can also be prescribed the drug.

The Health Ministry has also requested medical institutions to comply with the Food and Drug Safety Administration’s approval conditions. Before prescribing the medication, patients must be informed about potential side effects, which include gallbladder disease and pancreatitis, it said.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

International"I have actually stopped eight wars": Trump repeats claims he stopped war between India and Pakistan

InternationalUS House passes bill to release Epstein files, will now move to Senate

InternationalHigh-level delegation led by Andhra Governor to visit Saudi following tragic accident

InternationalJaishankar calls on President Putin; conveys greetings of PM Modi ahead of India-Russia Summit

InternationalRussian Helicopters unveils upgraded Ka-32A11M firefighting helicopter at Dubai Airshow 2025

Health Realted Stories

HealthFour more people die of dengue in Bangladesh, 2025 death toll crosses 340

HealthBrain fever: Karnataka govt releases guidelines for Sabarimala pilgrims

HealthPrevalence of multidrug-resistant organisms highest in Indian patients: Study

HealthIndian space sector to grow from $8 billion to $45 billion in next decade: Jitendra Singh 

HealthLeveraging AI can transform India’s healthcare landscape: Report